FDA advisory panels: technical input needs rank above COI (conflict of interest) issues
This article was originally published in Clinica
Executive Summary
The US FDA must give prior public notice before letting experts with a potential conflict of interest (COI) participate on advisory panels, according to a bill enacted by the US Congress last week.